Global PCR Multiplex Assays Market by Product Type (Reagents, PCR Instruments, Software), End-Use Industry (Hospitals, Diagnostic Laboratories, Research Institutions), Application (Infectious Disease Diagnosis, Genetic Testing, Cancer Diagnostics): Insights & Forecast (2024 – 2030)

As per Intent Market Research, the PCR Multiplex Assays Market was valued at USD 3.5 Billion in 2024-e and will surpass USD 7.0 Billion by 2030; growing at a CAGR of 12.1% during 2025 - 2030.

The PCR (Polymerase Chain Reaction) multiplex assays market is experiencing significant growth due to their increasing application in various fields such as infectious disease diagnosis, genetic testing, and cancer diagnostics. PCR multiplex assays allow the simultaneous amplification and detection of multiple targets in a single PCR experiment, offering greater efficiency, cost-effectiveness, and speed compared to traditional single-target PCR assays. The rising demand for quick and accurate diagnostics in clinical settings, particularly in hospitals and diagnostic laboratories, is driving the adoption of these assays. Moreover, advancements in PCR technologies and the growing focus on personalized medicine further contribute to the market’s expansion.

The PCR multiplex assays market is fueled by increasing investments in healthcare infrastructure, rapid advancements in diagnostic technologies, and the growing prevalence of infectious diseases and genetic disorders. Additionally, the rising demand for precision medicine, where multiplex assays play a critical role in identifying genetic variations and cancer biomarkers, is further enhancing the market’s growth potential.

Reagents Are Largest Segment Owing to Essential Role in PCR Testing

Reagents represent the largest product segment in the PCR multiplex assays market, primarily due to their essential role in the PCR testing process. Reagents are the key components used in PCR reactions, including primers, enzymes, buffers, and nucleotides, which are required to carry out the amplification and detection of DNA or RNA sequences. The demand for PCR reagents has surged in response to the increasing need for molecular diagnostics, particularly in infectious disease detection, genetic testing, and cancer diagnostics.

The continuous innovation in reagent formulations, such as the development of more efficient enzymes and optimized buffers, has improved the overall performance of PCR multiplex assays, further driving the demand for reagents. With the increasing number of diagnostic tests being performed across various applications, reagents are expected to remain the dominant product type in the PCR multiplex assays market.

Infectious Disease Diagnosis Segment Is Largest Application Area Owing to High Prevalence of Infectious Diseases

The infectious disease diagnosis segment is the largest application area for PCR multiplex assays, as these assays are critical for the detection of a wide range of pathogens, including bacteria, viruses, and fungi. The ability to detect multiple pathogens simultaneously with a single test makes PCR multiplex assays indispensable in diagnosing infectious diseases, especially in areas with a high prevalence of communicable diseases.

Infectious disease outbreaks, including influenza, COVID-19, and others, have further accelerated the demand for rapid, accurate diagnostic tests. PCR multiplex assays provide healthcare providers with a valuable tool for disease detection, making this segment the largest in the market.

Genetic Testing Segment Is Fastest Growing Application Area Owing to Increasing Focus on Personalized Medicine

The genetic testing segment is the fastest-growing application area for PCR multiplex assays, driven by the increasing adoption of personalized medicine and genetic-based diagnostics. PCR multiplex assays enable the simultaneous detection of multiple genetic markers associated with various diseases, providing valuable insights into genetic predispositions and mutations.

As healthcare shifts toward precision medicine, the ability to assess multiple genetic variations in a single test is becoming essential. This trend is fueling the rapid growth of PCR multiplex assays in genetic testing, particularly in research institutions and diagnostic laboratories focused on genetic disorders, cancer genomics, and pharmacogenomics.

North America Is Largest Region Owing to Advanced Healthcare Infrastructure and Strong Diagnostic Demand

North America holds the largest share of the PCR multiplex assays market, driven by its advanced healthcare infrastructure, high adoption of cutting-edge diagnostic technologies, and increasing demand for efficient diagnostic tools. The region benefits from well-established healthcare systems, where hospitals and diagnostic laboratories have adopted PCR multiplex assays for rapid and accurate disease detection. The rising incidence of infectious diseases, genetic disorders, and cancers, coupled with the growing need for personalized medicine, has further increased the demand for PCR multiplex assays in North America.

Additionally, the region is home to major players in the PCR diagnostics industry, which contributes to the development and distribution of innovative multiplex assays. North America’s leading position in healthcare technology adoption, along with its robust research and development efforts, ensures its continued dominance in the global PCR multiplex assays market.

Competitive Landscape and Key Players

The PCR multiplex assays market is highly competitive, with key players such as Thermo Fisher Scientific, Bio-Rad Laboratories, Roche, Abbott Laboratories, and Qiagen leading the industry. These companies offer a wide range of PCR instruments, reagents, and software solutions, focusing on innovation to improve assay efficiency, accuracy, and ease of use.

Leading companies are also focusing on strategic collaborations, mergers, and acquisitions to enhance their product offerings and expand their market presence. Furthermore, continuous advancements in PCR technology, such as real-time PCR and digital PCR, are driving competition in the market. As the demand for molecular diagnostics continues to rise, these companies are expected to play a significant role in shaping the future of the PCR multiplex assays market.

List of Leading Companies:

• Thermo Fisher Scientific
• Roche Diagnostics
• Abbott Laboratories
• Bio-Rad Laboratories
• QIAGEN
• Illumina
• PerkinElmer
• Agilent Technologies
• Siemens Healthineers
• Becton, Dickinson and Company
• Applied Biosystems (by Thermo Fisher)
• Hologic
• Cepheid
• Randox Laboratories
• Luminex Corporation

Recent Developments:

• Thermo Fisher Scientific launched a new PCR multiplex assay designed to detect a wider range of infectious diseases in a single test.
• Roche Diagnostics introduced an advanced PCR instrument for multiplex assays, enhancing the speed and precision of genetic testing.
• Abbott Laboratories expanded its PCR multiplex assay offerings with a new panel for detecting multiple respiratory pathogens.
• Bio-Rad Laboratories received regulatory approval for a new PCR multiplex assay designed for oncology applications.
• QIAGEN announced the launch of a next-generation PCR multiplex assay for simultaneous detection of multiple bacterial pathogens.

Report Scope: